subgroups is BRAF -mutated ( BRAF mt) CRC. BRAF mutations are present in roughly 10% of patients with mCRC 2 and portend a particularly unfavorable prognosis, with a median survival for patients with metastatic disease of <12 months. 3 , 4 BRAF mt mCRC
Search Results
Andrew Trunk, Matthew Braithwaite, Christopher Nevala-Plagemann, Lisa Pappas, Benjamin Haaland, and Ignacio Garrido-Laguna
Jarred Burkart, Dwight Owen, Manisha H. Shah, Sherif R. Z. Abdel-Misih, Sameek Roychowdhury, Robert Wesolowski, Sigurdis Haraldsdottir, Julie W. Reeser, Eric Samorodnitsky, Amy Smith, and Bhavana Konda
the need to develop effective targeted therapies that can produce durable responses. Targetable genetic features of high-grade NECs have not been comprehensively described. In a recent case series, Klempner et al 2 reported BRAF mutations in 9% of
Rona Yaeger and Leonard Saltz
a V600E BRAF mutation, and can that mutation be targeted for therapeutic advantage? BRAF as a Prognostic and Predictive Marker From a prognostic perspective, it is clear that BRAF mutations confer a particularly poor prognosis, regardless of
Chloe E. Atreya, Claire Greene, Ryan M. McWhirter, Nabia S. Ikram, I. Elaine Allen, Katherine Van Loon, Alan P. Venook, Benjamin M. Yeh, and Spencer C. Behr
high degree of CpG island methylation (CIMP-H). 3 – 10 BRAF mutations are more frequent in women, older patients, and in whites compared with Asians or blacks with CRC. 2 , 11 , 12 Importantly, BRAF V600E–mutated mCRC is associated with a poor
Rohan Maniar, Stephanie M. Gallitano, Sameera Husain, Golnaz Moazami, Michael J. Weiss, and Catherine A. Shu
% to 85% of all cases. 1 , 2 BRAF mutations have been described in a number of malignancies, including melanoma and colon cancer, and account for approximately 2% to 4% of NSCLC. 3 Although a number of BRAF mutations have been identified, clinical
Anthony J. Olszanski
.2019. Available at NCCN.org . Approximately half of all melanomas harbor a BRAF mutation; most commonly, these mutations are activating BRAF V600E or V600K mutations (only ∼8% of BRAF mutations are non-V600E/K). The second most common genomic alteration in
James S. Blachly, Gerard Lozanski, David M. Lucas, Michael R. Grever, Kari Kendra, and Leslie A. Andritsos
second melanoma resection were sent to the molecular diagnostics laboratory at The Ohio State University where BRAF mutation testing was performed. Briefly, in a Clinical Laboratory Improvement Amendments–certified procedure, the genomic DNA was
Karen L. Reckamp
Conference. 1 The list of mutations with approved targeted therapies includes EGFR mutations (present in 30%–40% of Asians 2 and 10%–20% of Caucasians), 3 ALK rearrangements (present in up to 7%), ROS1 rearrangements (1.7%), and BRAF mutations
Robin K. Kelley, Grace Wang, and Alan P. Venook
(MSI) testing in management of patients with stage II colon cancer Describe the role of KRAS mutational analysis in management of patients with metastatic colorectal cancers Describe the role of BRAF mutational analysis in management of patients with
Leora Horn
system is an important factor, given that approximately 50% of patients who are on crizotinib will progress with that as their site of disease,” added Dr. Horn. Targeting ROS1 and BRAF Mutations Similar to EGFR and ALK , both ROS1 fusions
